A Study To Describe The Use Of Tofacitinib After Use Of Rituximab In Patients With Rheumatoid Arthritis In A Real-World Setting

Pfizer

Status: Completed

Conditions: Arthritis, Rheumatoid

Study type: Observational

Funder types: Industry

Identifiers

NCT05487703

A3921420

Details and patient eligibility

About

This study is to characterize the use of tofacitinib after use of rituximab in patients with Rheumatoid Arthritis in a real-world setting.

Enrollment: 318 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Enrolled in the CorEvitas RA Registry and initiated tofacitinib on or after November 2012.
• Initiate tofacitinib (defined as first ever use of tofacitinib) at Registry enrollment visit or at a Registry follow-up visit after November 2012
• Have prior use of rituximab
• Have CDAI measured at baseline and appropriate follow-up visit.

Exclusion criteria

• There are no exclusion criteria for this study

Trial design

318 participants in 1 patient group

Clinical characteristics

Description:

clinical characteristics of adult patients with Rheumatoid Arthritis (RA) initiating tofacitinib